Emma Scott

8PUBLICATIONS

14CO-AUTHORS

Haematological tumoursInnate immunityMolecular targetsPredictive and prognostic markersMedical molecular engineering of nucleic acids and proteins

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|May 14, 2026

Tissue-specific factors that govern the sialoglycan-Siglec axis in cancer.

|May 26, 2025

A general and accessible approach to enrichment and characterisation of natural anti-Neu5Gc antibodies from human samples.

Esme Hutton, Yumiko Uno, Emma Scott

|Mar 06, 2024

ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.

Rebecca Garnham, Daniel Geh, Ryan Nelson

|Aug 07, 2023

ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.

Emma Scott, Emily Archer Goode, Rebecca Garnham

|Jul 29, 2023

CDC20 Is Regulated by the Histone Methyltransferase, KMT5A, in Castration-Resistant Prostate Cancer.

Zainab A H Alebady, Mahsa Azizyan, Sirintra Nakjang

|Jul 28, 2022

Pro-Survival Factor EDEM3 Confers Therapy Resistance in Prostate Cancer.

Emma Scott, Rebecca Garnham, Kathleen Cheung

Pageof 2

Frequent Collaborators

Jennifer Munkley

Craig Robson

Kelly Coffey

Mahsa Azizyan

Norman J Maitland

Ning Wang

Erik Ramon-Gil

Laura Walker

Matthew Macauley

Jack Leslie

Frequent Collaborators

Jennifer Munkley

Craig Robson

Kelly Coffey

Mahsa Azizyan